Multicenter Prospective Phase II Trial of Bevacizumab (bev) for Progressive Pancreatic Neuroendocrine Tumor (PNET).

4096 Background: Single agent trials of mTOR inhibitors and VEGF receptor TKIs in PNET yield response rates < 10%. We previously demonstrated a 39% PR rate in PNET with the combination of temsirolimus and bev in patients with progressive PNET. There are no data regarding the efficacy of single agent bev in PNET. Methods: We conducted a multicenter phase II trial of bev at a dose of 10 mg/kg IV q 2 weeks in patients (pts) with well or moderately differentiated PNET, adequate organ function, and ECOG PS of 0-1. Important eligibility criteria included requirement for progression of disease by RECIST within 7 months of study entry. No prior anti-VEGF pathway inhibitor therapy was allowed. Ongoing octreotide was allowed at stable dose if required for symptom control. Primary endpoint was response with null hypothesis of 10% and promising result was defined as 30%. Planned enrollment was 21 pts. Results: : 22 pts enrolled from 10/2012 through 6/2014 were eligible for The primary endpoint of response assessment....